MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Immune-based Therapies

Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma

JCI Insight 2018 April 5 [Epub ahead of print] [Link] Lee HS et. al. Asbstract We generated a comprehensive atlas of the immunologic cellular networks within human malignant pleural mesothelioma (MPM) using mass cytometry. Data-driven analyses of these high-resolution single-cell data identified 2 distinct immunologic subtypes of MPM with vastly different cellular composition, activation states, […]

Comments Off on Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma

Podoplanin – an emerging cancer biomarker and therapeutic target

Cancer Science 2018 March 25 [Epub ahead of print] [Link] Krishnan H et. al. Abstract Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts (CAFs), and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition (EMT), migration, invasion, metastasis, […]

Comments Off on Podoplanin – an emerging cancer biomarker and therapeutic target

Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma

Journal of Cellular and Molecular Medicine 2018 March 24 [Epub ahead of print] [Link] Hsu PC, et. al. Abstract Although tumour PD-L1 (CD274) expression had been used as a predictive biomarker in checkpoint immunotherapy targeting the PD1/PD-L1 axis in various cancers, the regulation of PD-L1 (CD274) expression is unclear. Yes-associated protein (YAP), an important oncogenic […]

Comments Off on Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

European Respiratory Review 2018 March [Print 2018 March 31] Link] Boyer A, Pasquier E, Tomasini P, Ciccolini J, Greillier L, Andre N, Barlesi F, Mascaux C Abstract Drug repurposing is the use of known drugs for new indications. Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. So far, few treatments have […]

Comments Off on Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

State of the Art: Advances in Malignant Pleural Mesothelioma in 2017

Journal of Thoracic Oncology 2018 March 7 [Epub ahead of print] [Link] McCambridge AJ et. al. Abstract Malignant pleural mesothelioma (MPM) is an uncommon, almost universally fatal, asbestos-induced malignancy. New and effective strategies for diagnosis, prognostication and treatment are urgently needed. Herein we review the advances in MPM achieved in 2017. While recent epidemiological data […]

Comments Off on State of the Art: Advances in Malignant Pleural Mesothelioma in 2017

Immunotherapy for thoracic oncology gone viral

Immunotherapy 2018 April [Link] Patel MR Abstract Immune therapy has now been incorporated into the standard of care for non-small-cell lung cancer based on randomized trials showing superiority of anti-PD1 antibodies compared with chemotherapy. Thus there is a renewed interest in immune approaches to treating lung cancer. One promising approach is with oncolytic viruses that […]

Comments Off on Immunotherapy for thoracic oncology gone viral

Malignant mesothelioma clinical trial combines immunotherapy drugs

Immunotherapy 2018 April [Link] Chatwal MS, Tanvetyanon T Abstract Immunotherapy by checkpoint inhibitor is effective for a number of solid tumors including malignant mesothelioma. Studies utilizing single-agent PD-1 or PD-L1 inhibitor for mesothelioma have reported tumor response rates in approximately 10-20% of patients treated. Given the success of combining these agents with CTLA-4 inhibitor in […]

Comments Off on Malignant mesothelioma clinical trial combines immunotherapy drugs

Anti-tumor immunotherapy in malignant pleural mesothelioma

Rev Mal Respir 2018 February 4 [Epub ahead of print] [Link] Scherpereel A, Willemin MC, Wasielewski E, Dhalluin X Abstract INTRODUCTION: Malignant pleural mesothelioma (MPM) is a quite rare cancer, but with increasing incidence, that is usually induced by previous asbestos exposure. Its prognosis is poor and there is no validated curative therapy to date. […]

Comments Off on Anti-tumor immunotherapy in malignant pleural mesothelioma

Search for biomarkers of asbestos exposure and asbestos-induced cancers in investigations of the immunological effects of asbestos

Environmental Health and Preventative Medicine 2017 June [Link] Matsuzaki H et.al. Abstract The immunological effects of asbestos exposure on various lymphocytes such as the regulatory T cell (Treg), responder CD4+ T helper cell (Tresp), CD8+ cytotoxic T lymphocytes (CTL), and natural killer (NK) cells were investigated. Results show that asbestos exposure impairs antitumor immunity through […]

Comments Off on Search for biomarkers of asbestos exposure and asbestos-induced cancers in investigations of the immunological effects of asbestos

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients

Oncotarget 2017 September [Link] Marcq E Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with an increasing incidence, poor prognosis and limited effective treatment options. Hence, new treatment strategies are warranted which include immune checkpoint blockade approaches with encouraging preliminary data. Research on the immunological aspects of the easily accessible mesothelioma microenvironment could identify […]

Comments Off on Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients